Longitudinal Evaluation of Humoral Immunity and Bacterial and Clinical Parameters Reveals That Antigen-Specific Antibodies Suppress Inflammatory Responses in Active Tuberculosis Patients
A novel tuberculosis vaccine to replace BCG has long been desired. However, recent vaccine trials focused on cell-mediated immunity have failed to produce promising results. It is worth noting that most commercially available successful vaccines rely on humoral immunity. To establish a basic underst...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2018/4928757 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566677525495808 |
|---|---|
| author | Mamiko Niki Takashi Yoshiyama Yuji Miyamoto Masao Okumura Makoto Niki Ken-ichi Oinuma Yukihiro Kaneko Sohkichi Matsumoto Yuka Sasaki Hideo Ogata Hajime Goto Shoji Kudoh Yoshihiko Hoshino |
| author_facet | Mamiko Niki Takashi Yoshiyama Yuji Miyamoto Masao Okumura Makoto Niki Ken-ichi Oinuma Yukihiro Kaneko Sohkichi Matsumoto Yuka Sasaki Hideo Ogata Hajime Goto Shoji Kudoh Yoshihiko Hoshino |
| author_sort | Mamiko Niki |
| collection | DOAJ |
| description | A novel tuberculosis vaccine to replace BCG has long been desired. However, recent vaccine trials focused on cell-mediated immunity have failed to produce promising results. It is worth noting that most commercially available successful vaccines rely on humoral immunity. To establish a basic understanding of humoral immunity against tuberculosis, we analyzed and evaluated longitudinal levels and avidity of immunoglobulin to various tuberculosis antigens compared with bacterial and clinical parameters during treatment. We found that levels of IgG antibodies against HrpA and HBHA prior to treatment exhibited a positive correlation with bacterial burden. Analysis of changes in CRP during treatment revealed an association with high levels of specific IgG and IgA antibodies against mycobacterial antigens. Levels of CRP prior to treatment were negatively associated with IgG avidity to CFP-10 and MDP1 and IgA avidity to HrpA, while IgA avidity to MDP1 and Acr exhibited a negative correlation with CRP levels after 60 days of treatment. These results may provide insight for the development of a novel tuberculosis (TB) vaccine candidate to induce protective humoral immunity against tuberculosis. |
| format | Article |
| id | doaj-art-57c3c8d479484ebdb79504f666326ee1 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-57c3c8d479484ebdb79504f666326ee12025-02-03T01:03:23ZengWileyJournal of Immunology Research2314-88612314-71562018-01-01201810.1155/2018/49287574928757Longitudinal Evaluation of Humoral Immunity and Bacterial and Clinical Parameters Reveals That Antigen-Specific Antibodies Suppress Inflammatory Responses in Active Tuberculosis PatientsMamiko Niki0Takashi Yoshiyama1Yuji Miyamoto2Masao Okumura3Makoto Niki4Ken-ichi Oinuma5Yukihiro Kaneko6Sohkichi Matsumoto7Yuka Sasaki8Hideo Ogata9Hajime Goto10Shoji Kudoh11Yoshihiko Hoshino12Department of Bacteriology, Osaka City University Graduate School of Medicine, Abeno, Osaka 545-8585, JapanDivision of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo 204-8522, JapanDepartment of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, Aoba, Higashi-Murayama, Tokyo 189-0002, JapanDivision of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo 204-8522, JapanDepartment of Bacteriology, Osaka City University Graduate School of Medicine, Abeno, Osaka 545-8585, JapanDepartment of Bacteriology, Osaka City University Graduate School of Medicine, Abeno, Osaka 545-8585, JapanDepartment of Bacteriology, Osaka City University Graduate School of Medicine, Abeno, Osaka 545-8585, JapanDepartment of Bacteriology, Niigata University Graduate School of Medicine, Niigata 951-8510, JapanDivision of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo 204-8522, JapanDivision of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo 204-8522, JapanDivision of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo 204-8522, JapanDivision of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo 204-8522, JapanDepartment of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, Aoba, Higashi-Murayama, Tokyo 189-0002, JapanA novel tuberculosis vaccine to replace BCG has long been desired. However, recent vaccine trials focused on cell-mediated immunity have failed to produce promising results. It is worth noting that most commercially available successful vaccines rely on humoral immunity. To establish a basic understanding of humoral immunity against tuberculosis, we analyzed and evaluated longitudinal levels and avidity of immunoglobulin to various tuberculosis antigens compared with bacterial and clinical parameters during treatment. We found that levels of IgG antibodies against HrpA and HBHA prior to treatment exhibited a positive correlation with bacterial burden. Analysis of changes in CRP during treatment revealed an association with high levels of specific IgG and IgA antibodies against mycobacterial antigens. Levels of CRP prior to treatment were negatively associated with IgG avidity to CFP-10 and MDP1 and IgA avidity to HrpA, while IgA avidity to MDP1 and Acr exhibited a negative correlation with CRP levels after 60 days of treatment. These results may provide insight for the development of a novel tuberculosis (TB) vaccine candidate to induce protective humoral immunity against tuberculosis.http://dx.doi.org/10.1155/2018/4928757 |
| spellingShingle | Mamiko Niki Takashi Yoshiyama Yuji Miyamoto Masao Okumura Makoto Niki Ken-ichi Oinuma Yukihiro Kaneko Sohkichi Matsumoto Yuka Sasaki Hideo Ogata Hajime Goto Shoji Kudoh Yoshihiko Hoshino Longitudinal Evaluation of Humoral Immunity and Bacterial and Clinical Parameters Reveals That Antigen-Specific Antibodies Suppress Inflammatory Responses in Active Tuberculosis Patients Journal of Immunology Research |
| title | Longitudinal Evaluation of Humoral Immunity and Bacterial and Clinical Parameters Reveals That Antigen-Specific Antibodies Suppress Inflammatory Responses in Active Tuberculosis Patients |
| title_full | Longitudinal Evaluation of Humoral Immunity and Bacterial and Clinical Parameters Reveals That Antigen-Specific Antibodies Suppress Inflammatory Responses in Active Tuberculosis Patients |
| title_fullStr | Longitudinal Evaluation of Humoral Immunity and Bacterial and Clinical Parameters Reveals That Antigen-Specific Antibodies Suppress Inflammatory Responses in Active Tuberculosis Patients |
| title_full_unstemmed | Longitudinal Evaluation of Humoral Immunity and Bacterial and Clinical Parameters Reveals That Antigen-Specific Antibodies Suppress Inflammatory Responses in Active Tuberculosis Patients |
| title_short | Longitudinal Evaluation of Humoral Immunity and Bacterial and Clinical Parameters Reveals That Antigen-Specific Antibodies Suppress Inflammatory Responses in Active Tuberculosis Patients |
| title_sort | longitudinal evaluation of humoral immunity and bacterial and clinical parameters reveals that antigen specific antibodies suppress inflammatory responses in active tuberculosis patients |
| url | http://dx.doi.org/10.1155/2018/4928757 |
| work_keys_str_mv | AT mamikoniki longitudinalevaluationofhumoralimmunityandbacterialandclinicalparametersrevealsthatantigenspecificantibodiessuppressinflammatoryresponsesinactivetuberculosispatients AT takashiyoshiyama longitudinalevaluationofhumoralimmunityandbacterialandclinicalparametersrevealsthatantigenspecificantibodiessuppressinflammatoryresponsesinactivetuberculosispatients AT yujimiyamoto longitudinalevaluationofhumoralimmunityandbacterialandclinicalparametersrevealsthatantigenspecificantibodiessuppressinflammatoryresponsesinactivetuberculosispatients AT masaookumura longitudinalevaluationofhumoralimmunityandbacterialandclinicalparametersrevealsthatantigenspecificantibodiessuppressinflammatoryresponsesinactivetuberculosispatients AT makotoniki longitudinalevaluationofhumoralimmunityandbacterialandclinicalparametersrevealsthatantigenspecificantibodiessuppressinflammatoryresponsesinactivetuberculosispatients AT kenichioinuma longitudinalevaluationofhumoralimmunityandbacterialandclinicalparametersrevealsthatantigenspecificantibodiessuppressinflammatoryresponsesinactivetuberculosispatients AT yukihirokaneko longitudinalevaluationofhumoralimmunityandbacterialandclinicalparametersrevealsthatantigenspecificantibodiessuppressinflammatoryresponsesinactivetuberculosispatients AT sohkichimatsumoto longitudinalevaluationofhumoralimmunityandbacterialandclinicalparametersrevealsthatantigenspecificantibodiessuppressinflammatoryresponsesinactivetuberculosispatients AT yukasasaki longitudinalevaluationofhumoralimmunityandbacterialandclinicalparametersrevealsthatantigenspecificantibodiessuppressinflammatoryresponsesinactivetuberculosispatients AT hideoogata longitudinalevaluationofhumoralimmunityandbacterialandclinicalparametersrevealsthatantigenspecificantibodiessuppressinflammatoryresponsesinactivetuberculosispatients AT hajimegoto longitudinalevaluationofhumoralimmunityandbacterialandclinicalparametersrevealsthatantigenspecificantibodiessuppressinflammatoryresponsesinactivetuberculosispatients AT shojikudoh longitudinalevaluationofhumoralimmunityandbacterialandclinicalparametersrevealsthatantigenspecificantibodiessuppressinflammatoryresponsesinactivetuberculosispatients AT yoshihikohoshino longitudinalevaluationofhumoralimmunityandbacterialandclinicalparametersrevealsthatantigenspecificantibodiessuppressinflammatoryresponsesinactivetuberculosispatients |